Inactive Instrument

QuantRx Biomedical Corporation Stock Other OTC

Equities

QTXB

US74765N1090

Advanced Medical Equipment & Technology

Sales 2020 - Sales 2021 - Capitalization 787K
Net income 2020 - Net income 2021 - EV / Sales 2020 -
Net Debt 2020 1.5M Net Debt 2021 1.56M EV / Sales 2021 -
P/E ratio 2020
-1.87 x
P/E ratio 2021
-3.03 x
Employees -
Yield 2020 *
-
Yield 2021
-
Free-Float 92.7%
More Fundamentals * Assessed data
Dynamic Chart
QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical Corporation CI
QuantRx Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
QuantRx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
QuantRx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
QuantRx Biomedical Corporation Auditor Raises 'Going Concern' Doubt CI
QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Quantrx Biomedical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Quantrx Biomedical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
More news
Managers TitleAgeSince
Chief Executive Officer 87 05-08-31
Members of the board TitleAgeSince
Chief Executive Officer 87 05-08-31
More insiders
QuantRx Biomedical Corporation has developed its patented miniform pads and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs (the OTC Business). The Company is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents (the Diagnostics Business). The Company's platforms include inSync, Unique and original equipment manufacturer (OEM) branded over-the-counter and laboratory testing products based on its core intellectual property related to the Company PAD technology. Its OTC Business includes commercialization of its InSync feminine hygienic interlabial pad, the Unique Miniform for hemorrhoid application, and other treated miniforms, as well as maintaining established and continuing licensing relationships related to the OTC Business. It also owns certain diagnostic testing technology that is based on its lateral flow patents.
More about the company